Candel Therapeutics, Inc. Common Stock

CADLNASDAQ • USD
5.81 USD
↘ 0.39 (6.29%)AT CLOSE (03:59 PM EST)
5.87
↗ 0.06 (0.95%)
POST MARKET (AS OF 07:06 PM EST)
Post Market
AS OF 07:06 PM EST
5.87
↗ 0.06 (0.95%)
🟢Market: OPEN

Candel Therapeutics, Inc. Common Stock (CADL) trades at $5.87 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. CADL is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of Nov 16, 2026.

Open?$5.94
High?$6.23
Low?$5.73
Prev. Close?$6.20
Volume?3.3M
Avg. Volume?1.3M
VWAP?$5.97
Rel. Volume?2.58x
Bid / Ask
Bid?$4.91 × 100
Ask?$7.04 × 100
Spread?$2.13
Midpoint?$5.98
Valuation & Ratios
Market Cap?486.4M
Shares Out?76.5M
Float?59.3M
Float %?77.5%
P/E Ratio?N/A
P/B Ratio?3.70
EPS?-$1.26
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Employees
55
Market Cap
486.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-07-27
Address
117 KENDRICK STREET
NEEDHAM, MA 02494
Phone: 617-916-5445
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
19
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?1.43Distress
Confidence?60%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?22.08%Squeeze Risk
Short Interest?13.1M
Days to Cover?13.3
Free Float59.3M
Avg Daily Volume983.3K
Settlement Date2026-10-30
Financial Health
Current Ratio?7.57Strong
Quick Ratio?7.57Strong
Cash Ratio?7.42Strong
Debt/Equity?0.37Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
47
3.70FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-4.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-75.3%WEAK▾
ROA?
S&P
3
-47.0%WEAK▾
Cash Flow & Enterprise
FCF?$-70200000
Enterprise Value?$331.4M
Fundamentals ratios updated end of day